Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca Stock Rises as US, Cancer Drug Growth Lifts Q2 Results
09:35am, Tuesday, 29'th Jul 2025
AstraZeneca (AZN) shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.
AstraZeneca results: H1 and Q2 2025
07:00am, Tuesday, 29'th Jul 2025
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2025 % Change Q2 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Reven
AstraZeneca maintains outlook as pipeline delivers strong late-stage results
02:54am, Tuesday, 29'th Jul 2025
AstraZeneca PLC (LSE:AZN) has reiterated its full-year guidance for 2025, following a robust set of results for the second quarter and first half, and pointed to a series of significant late-stage tr
AstraZeneca beats second-quarter profit expectations, maintains outlook
02:05am, Tuesday, 29'th Jul 2025
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and g
AstraZeneca share price forecast after earnings
02:02am, Tuesday, 29'th Jul 2025
AstraZeneca share price held steady this week after the company published strong financial results on Tuesday. AZN stock was trading at 10,790p, a range it has remained in the past few days.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
11:31am, Monday, 28'th Jul 2025
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study
07:49am, Monday, 28'th Jul 2025
Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket tra
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
07:16pm, Friday, 25'th Jul 2025
In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.
AstraZeneca's eco-friendly version of smoker's lung inhaler gets EU panel backing
06:16am, Friday, 25'th Jul 2025
A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.
Insights Into Astrazeneca (AZN) Q2: Wall Street Projections for Key Metrics
10:16am, Thursday, 24'th Jul 2025
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
AstraZeneca's immune disorder drug succeeds in late-stage trial
03:27am, Thursday, 24'th Jul 2025
AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised myasth
5 Ideal "Safer" Dividend Buys From Bloomberg's July Watch List
02:52pm, Tuesday, 22'nd Jul 2025
Bloomberg's 50 Companies to Watch leverages catalysts like new leadership, AI, and policy shifts to identify high-potential stocks for 2025. Yield-based 'dogcatcher' analysis spotlights 15 dividend pa
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
02:21pm, Tuesday, 22'nd Jul 2025
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to Presi
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
12:46pm, Tuesday, 22'nd Jul 2025
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
AstraZeneca to invest $50B in US to boost drug manufacturing and R&D
12:26pm, Tuesday, 22'nd Jul 2025
AstraZeneca PLC (LSE:AZN) has announced plans to invest $50 billion in the United States by 2030, marking the pharmaceutical giant's largest-ever investment in a single market. The UK-headquartered bi
